TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

SULINDAC

SULINDAC Cyclooxygenase Inhibitors
Immunology Approved 1988-03-03
7
Indications
--
Phase 3 Trials
38
Years on Market

Details

Status
Prescription
First Approved
1988-03-03
Routes
ORAL
Dosage Forms
TABLET

SULINDAC Approval History

Loading approval history...

What SULINDAC Treats

6 indications

SULINDAC is approved for 6 conditions since its original approval in 1988. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Osteoarthritis
  • Rheumatoid Arthritis
  • Ankylosing Spondylitis
  • Subacromial Bursitis
  • Supraspinatus Tendinitis
  • Gouty Arthritis
Source: FDA Label

SULINDAC Boxed Warning

Cardiovascular Thrombotic Events Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use [see Warnings and Precautions ]. Sulindac tablets are contraindicated in the setting of coronary artery bypass graft (CABG) surgery [see Contraindications and Warnings]. Gastrointestinal Risk NSAIDs cause an inc...

Drugs Similar to SULINDAC

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

CELEBREX
CELECOXIB
3 shared
GD SEARLE LLC
Shared indications:
OsteoarthritisRheumatoid ArthritisAnkylosing Spondylitis
CORTEF
HYDROCORTISONE
3 shared
PHARMACIA AND UPJOHN
Shared indications:
Rheumatoid ArthritisAnkylosing SpondylitisGouty Arthritis
EC-NAPROSYN
NAPROXEN
3 shared
ATNAHS PHARMA US
Shared indications:
Rheumatoid ArthritisOsteoarthritisAnkylosing Spondylitis
ELYXYB
CELECOXIB
3 shared
SCILEX PHARMS
Shared indications:
OsteoarthritisRheumatoid ArthritisAnkylosing Spondylitis
NAPRELAN
NAPROXEN SODIUM
3 shared
TWI PHARMS
Shared indications:
Rheumatoid ArthritisOsteoarthritisAnkylosing Spondylitis
NAPROSYN
NAPROXEN
3 shared
ATNAHS PHARMA US
Shared indications:
Rheumatoid ArthritisOsteoarthritisAnkylosing Spondylitis
NAPROXEN AND ESOMEPRAZOLE MAGNESIUM
ESOMEPRAZOLE MAGNESIUM
3 shared
Dr. Reddy's
Shared indications:
OsteoarthritisRheumatoid ArthritisAnkylosing Spondylitis
PREDNISONE INTENSOL
PREDNISONE
3 shared
Hikma
Shared indications:
Rheumatoid ArthritisAnkylosing SpondylitisGouty Arthritis
VYSCOXA
CELECOXIB
3 shared
CARWIN PHARM ASSOC
Shared indications:
OsteoarthritisRheumatoid ArthritisAnkylosing Spondylitis
ABRILADA
ADALIMUMAB-AFZB
2 shared
Pfizer
Shared indications:
Rheumatoid ArthritisAnkylosing Spondylitis
AMJEVITA
ADALIMUMAB-ATTO
2 shared
Amgen
Shared indications:
Rheumatoid ArthritisAnkylosing Spondylitis
ARTHROTEC
DICLOFENAC SODIUM
2 shared
Pfizer
Shared indications:
OsteoarthritisRheumatoid Arthritis
CATAFLAM
DICLOFENAC POTASSIUM
2 shared
AMICI PHARMA
Shared indications:
OsteoarthritisRheumatoid Arthritis
CIMZIA
CERTOLIZUMAB PEGOL
2 shared
UCB INC
Shared indications:
Rheumatoid ArthritisAnkylosing Spondylitis
COXANTO
OXAPROZIN
2 shared
SOLUBIOMIX
Shared indications:
OsteoarthritisRheumatoid Arthritis
CYLTEZO
ADALIMUMAB-ADBM
2 shared
Boehringer Ingelheim
Shared indications:
Rheumatoid ArthritisAnkylosing Spondylitis
DAYPRO
OXAPROZIN
2 shared
Pfizer
Shared indications:
OsteoarthritisRheumatoid Arthritis
DICLOFENAC POTASSIUM
DICLOFENAC POTASSIUM
2 shared
INGENUS PHARMS LLC
Shared indications:
OsteoarthritisRheumatoid Arthritis
DICLOFENAC SODIUM AND MISOPROSTOL
DICLOFENAC SODIUM
2 shared
MICRO LABS
Shared indications:
OsteoarthritisRheumatoid Arthritis
DIFLUNISAL
DIFLUNISAL
2 shared
Teva
Shared indications:
OsteoarthritisRheumatoid Arthritis
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

SULINDAC FDA Label Details

Pro

Indications & Usage

Carefully consider the potential benefits and risks of sulindac tablets and other treatment options before deciding to use sulindac tablets. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). Sulindac tablets are indicated for acute or long-term use in the relief of signs and symptoms of the following: Osteoarthritis Rheumatoid arthritis* Ankylosing spondylitis Acute painful shoulder (Acute subacromial bursitis/supraspinatus tendinitis) Acute gouty arthritis

⚠️ BOXED WARNING

Cardiovascular Thrombotic Events Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use [see Warnin...

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.